AdityaBardiaMD

Oncology • Santa Monica, CA

Attending Physician, Massachusetts General Hospital, Harvard Medical School

Join to view full profile

Dr. Bardia is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bardia's full profile

Already have an account?

Office
2336 Santa Monica Blvd
Ste 304
Santa Monica, CA 90404
Phone+1 310-998-4747

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2008 - 2011
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2005 - 2008
All India Institute of Medical SciencesClass of 2003

Certifications & Licensure

CA State Medical License 2024 - 2026
MA State Medical License 2011 - 2025
MD State Medical License 2008 - 2012
MN State Medical License 2007 - 2008
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor Start of enrollment: 2012 Aug 07
Completed
Phase 3
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer Start of enrollment: 2012 Aug 01
Completed
Phase 2
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Start of enrollment: 2012 Dec 17
Completed
Phase 1, Phase 2
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer Start of enrollment: 2014 Dec 29
Terminated
Phase 1, Phase 2
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Start of enrollment: 2013 Sep 06
Completed
Phase 1
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) Start of enrollment: 2013 Oct 01
Terminated
Phase 2
Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) Start of enrollment: 2017 Nov 07
Completed
Phase 3
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. Start of enrollment: 2016 Mar 09
Completed
Phase 1, Phase 2
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer Start of enrollment: 2017 Dec 12
Recruiting
Phase 2
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer Start of enrollment: 2017 Nov 08
Terminated
Phase 1
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) Start of enrollment: 2019 May 30
Active, not recruiting
Phase 1
A Study of TAS-120 in Patients With Metastatic Breast Cancer Start of enrollment: 2019 Aug 30
Active, not recruiting
Phase 2
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. Start of enrollment: 2019 Oct 09
Recruiting
Phase 1, Phase 2
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer Start of enrollment: 2019 Dec 10
Active, not recruiting
Phase 1
A Study of LY3484356 in Women With Breast Cancer Before Having Surgery Start of enrollment: 2021 Apr 21
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Grow...
Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn, Cynthia X Ma, Erika P Hamilton
Journal of Clinical Oncology. 2024-12-10
3 citations
Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy ...
Aditya Bardia, Javier Cortés, François-Clément Bidard, Patrick Neven, José Garcia-Sáenz
Clinical Cancer Research. 2024-10-01
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer.
Maxwell R Lloyd, Komal Jhaveri, Kevin Kalinsky, Aditya Bardia, Seth A Wander
Nature Reviews. Clinical Oncology. 2024-10-01

Journal Articles

Targeted Therapy for Premenopausal Women with HR+, HER2- Advanced Breast Cancer: Focus on Special Considerations and Latest Advances
Aditya Bardia, MD, Clinical Cancer Research
A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer
David T Miyamoto, Aditya Bardia, Lecia V Sequist, Laura M Spring, Daniel A Haber, Mark Kalinich, Clinical Cancer Research

Lectures

Phase 1/2 dose-escalation and expansion study investigating SAR439859 +/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2- metastatic br...
2019 ASCO Annual Meeting - 6/1/2019
Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2âˆ’ advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safe...
2019 ASCO Annual Meeting - 6/1/2019
Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2- metastatic breast cancer (mBC).
2019 ASCO Annual Meeting - 6/1/2019
EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigatorâ€™s choice (IC) of endocrine therap...
2019 ASCO Annual Meeting - 6/1/2019
Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreati...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Join now to see all

Press Mentions

Cancer Drug Dosing Concerns Highlighted by Patient-Led StudyAugust 13th, 2024
Advancements in HER2-Directed Therapies Abound for HER2+ Metastatic Breast CancerJuly 10th, 2024
Janice Kim, MD, on Finding the Right Treatment Dose for Patients with Metastatic Breast CancerJuly 2nd, 2024
Join now to see all